My research team is focused on human parasites of major relevance to the Australian water industry and/or global public health. Our primary focus is the use of advanced technologies to improve understanding of these parasites and to utilize this information to underpin development of new drugs to treat them and novel diagnostic tests to improve their control.
Biostatistical Innovation And Capacity Building To Advance Child Health And Life-course Epidemiology
Funder
National Health and Medical Research Council
Funding Amount
$470,144.00
Summary
Biostatistics is a critical component of health and medical research. The proposed program of novel biostatistical research into methods for analysing incomplete data, an extensive portfolio of collaborative research in infant development, and establishment of a national biostatistics network, will facilitate my ongoing leadership in this critical discipline as well as enhancing the international standing of biostatistics in Australia.
Structural And Drug Discovery Studies Of Medically Important Protein Complexes
Funder
National Health and Medical Research Council
Funding Amount
$438,577.00
Summary
My research is focused on structural studies of medically important biological systems, where specific protein complex formation contributes to human illnesses. I use X-ray crystallography to visualize the whole complex at atomic resolution as well as to determine whether binding partners have undergone changes in shape upon complex formation. This structural information then helps me in drug design with goals to either disrupt or modulate the complex.
Optimising Treatment As Prevention Strategies For Hepatitis C And HIV
Funder
National Health and Medical Research Council
Funding Amount
$471,809.00
Summary
New evidence shows how hepatitis C (HCV) and HIV transmission can be reduced dramatically through timely treatment initiation - treatment as prevention (TasP). TasP has re-focused attention on early HCV and HIV detection and treatment. Through observational studies, randomised control trials and the development of innovative surveillance systems, this fellowship will inform ways to maximise the potential of HCV and HIV prevention responses in Australia and internationally in this new TasP era.
The Hunt For New-generation Lipopeptide Antibiotics Targeting Gram-negative ‘Superbugs’
Funder
National Health and Medical Research Council
Funding Amount
$473,477.00
Summary
The dry antibiotic discovery and development pipeline, together with the increasing incidence of bacterial resistance in the clinic has been dubbed ‘the perfect storm’. This project involves the design, synthesis and preclinical evaluation of a new generation of polymyxin-like lipopeptides that have low nephrotoxicity and specifically target polymyxin-resistant Gram-negative ‘superbugs’.
Follicular Helper T Cell Development And Function: From Mechanisms To Application
Funder
National Health and Medical Research Council
Funding Amount
$401,361.00
Summary
Antibodies are the basis of most successful vaccinations. Diminished antibody responses lead to immunodeficiency while excessive antibody responses contribute to autoimmune diseases. We are studying a newly identified specialised helper T cell subset, termed follicular helper T cells, which is essential to regulate the high-affinity and long-lived antibody responses. The knowledge should provide new strategies to design better vaccines, to control infections, or to treat autoimmune disorders.
Investigations Into Supraphysiologic T Cell Receptors And T Cell Agonists.
Funder
National Health and Medical Research Council
Funding Amount
$408,388.00
Summary
T cells are critical in controlling infection and important for the natural eradication of cancer. Through shape recognition, T cells identify dangerous antigens via the surface-bound T cell receptor (TCR). Using new technologies this project aims to "tune up" the strength of this molecular interaction and create a new generation of high affinity TCR and antigens for use as therapeutic and prophylactic drugs in the battle against infectious disease and cancer.
Monoclonal antibodies, such as the breast cancer therapeutic Herceptin, have revolutionised the treatment of cancer and inflammatory conditions. Will over $30 billion sales in 2011, they have also spawned a growing biotech industry. We have a generated a highly specific monoclonal antibody, which has shown efficacy in models of disease. This project will further advance and develop this monoclonal, allowing us to initiate clinical studies in patients.